Page 61 - Aet News Today

AstraZeneca gains global rights to an oral GLP-1 agonist on track to reach Phase 2 testing in 2024. Under China-based Eccogene, the small molecule’s Phase 1 data show reductions in glucose and body weight.

Putting all the AI pieces into place effectively requires clarity of what organizations want to accomplish - and for much of healthcare, the Quadruple Aim remains at the very top. Although how to get there will look different, clarity on principles and values that will guide the development of what comes next is paramount to setting us up for years to come.

The Heali app, which launched Thursday, offers personalized nutrition plans for more than 200 chronic conditions, including diabetes, allergies, autoimmune issues and gastrointestinal issues. Users can also access nutrition studies that explain the benefits of certain foods, as well as recipes that fit their diet.

Food insecurity is a blight that affects many. According to the Department of Agriculture, 12.8 percent (17.0 million households) were food insecure. The percentage of  food insecure household was statistically significantly higher than the 10.2 percent recorded in 2021 (13.5 million households) and the 10.5 percent in 2020 (13.8 million households). But there are ways to battle this. Here are four ways by which emerging technologies can reduce food insecurity. Precision agriculture: The Assoc...

Hera Biotech, a San Antonio-based startup developing a nonsurgical diagnostic test for endometriosis, won the Pitch Perfect contest at MedCity News’ INVEST Digital Health conference. The average diagnostic delay for the endometriosis is eight years, driven in large part by the fact that the only method currently used to diagnose the disease is a surgical procedure.

People with obesity should be offered a range of suitable treatments as well: behavioral, nutrition, exercise, medication and surgery, through a coordinated and holistic approach under one roof, with a care coordinator. Like cancer, obesity is a heterogeneous disease and recommendations and responses to all treatment modalities will be heterogeneous as well.

It was expected that the Affordable Care Act would lead to many employers dropping health benefits, but that did not happen, a new report from the Employee Benefit Research Institute found.

Celldex drug barzolvolimab has mid-stage results in a chronic inflammatory skin disease that top those of an approved Genentech drug and two experimental Novartis therapies. The biotech is preparing to advance its drug to Phase 3 testing in 2024.

Discussions around healthcare's workforce crisis usually center around providers’ lack of clinicians, but there’s a sweeping shortage of revenue cycle workers, too. In a new report, Experian Health surveyed 200 employees who are responsible for staffing the revenue cycle function at providers — every respondent said that staff shortages are having a significant negative impact on their organization’s ability to get paid for care and/or patient engagement.

About half (47%) of nonelderly uninsured veterans will be eligible for Medicaid or subsidies through the ACA Marketplace in 2024, according to a new report from the Urban Institute.